

Product datasheet for **TA389184**

CD274 Mouse Antibody [Clone ID: M080]

Product data:

Product Type:	Primary Antibodies
Clone Name:	M080
Applications:	ICC, IP, WB
Recommended Dilution:	WB: 1:500 ICC: 1:200
Reactivity:	Human
Host:	Mouse
Isotype:	IgG1
Immunogen:	Clone (M080) was generated from a recombinant protein that included the extracellular region of human PD-L1 protein.
Specificity:	Clone M080 mouse monoclonal antibody detects a 45-55 kDa* protein on SDS-PAGE "Native" or denatured immunoblots of human recombinant PD-L1 extracellular region, and human lung tissue. The antibody works for western blot, immunoprecipitation, immunocytochemistry, and ELISA capture.
Formulation:	PBS + 1 mg/ml BSA, 0.05% NaN ₃ and 50% glycerol
Concentration:	lot specific
Purification:	Protein G Purified
Conjugation:	Unconjugated
Storage:	Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C.
Stability:	After date of receipt, stable for at least 1 year at -20°C.
Predicted Protein Size:	45-55
Database Link:	Q9NZQ7



[View online »](#)

Background:

Programmed cell death 1 ligand 1 (PD-L1, B7-H1, CD274) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. The B7 family members have conserved regions that include extracellular IgV and IgC domains, and a short cytoplasmic region. Research studies demonstrate that PD-L1 is expressed in several tumor types, including melanoma, ovary, colon, lung, breast, and renal cell carcinomas. PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, which promotes tumor survival. The blockage of the PD1/PD-L1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. Several therapies that target PD1/PD-L1 pathways are currently in use or in clinical trials

Note:

Protein G purified tissue culture supernatant.